Home / 2020 / October / 21

Daily Archives: October 21, 2020

Forbes recognizes TELUS as Canada’s leading global workplace in World’s Best Employers 2020

The employee-sourced ranking placed TELUS #1 in Canada and 40th in the world among 750 global corporations

VANCOUVER, British Columbia, Oct. 21, 2020 (GLOBE NEWSWIRE) — Today, TELUS proudly announced that it has been recognized as Canada’s leading global workplace by Forbes World’s Best Employers 2020. TELUS, including TELUS International, was ranked first among 25 Canadian companies recognized by Forbes and was heralded as 40th globally, listed alongside 750 leading worldwide brands. This is an exciting achievement for TELUS as it continues to leverage its outstanding workplace culture to both empower and equip its team to embrace change, initiate opportunity, have the courage to innovate, and engage in spirited teamwork. TELUS’ differentiated and deeply-rooted culture enabled the team to rapidly evolve its operations and service to keep its customers and communities safe and connected during COVID-19.

“TELUS’ recognition as the highest ranking Canadian organization on Forbes’ World’s Best Employers ranking is a true reflection of and testament to the expertise, passion and commitment of our high-performing team, and the extraordinary, globally admired culture that underpins it,” said Darren Entwistle, President and CEO, TELUS. “As one of the largest private sector employers in Canada and with our TELUS International operations spanning 20 countries, our team is exceedingly proud that our global leadership in social capitalism, our longstanding values of diversity and inclusion, and our unwavering commitment to improving the social, economic and health outcomes of communities around the world, are being recognized in this way.”

Since March, as the world learned to grapple with the COVID-19 crisis, TELUS’ firmly entrenched values and culture enabled its team to adapt, innovate, and act with intention at an accelerated pace. TELUS has committed more than $150 million during the past several months to support Canadians through COVID-19. The TELUS team pivoted all of its philanthropic funding channels, including the TELUS Friendly Future Foundation and TELUS Community Boards, 13 in Canada and five international, to focus on health initiatives that support charities on the front line of the public health crisis. TELUS also donated 14,000 free devices and free rate plans, valued at $8-million to keep Canada’s most vulnerable citizens connected and also supported frontline healthcare workers at hospitals and long-term care facilities with two months of free mobility service.

“We are honoured to be named on Forbes’ World’s Best Employers 2020 ranking and humbled that the nomination originates from our team members across North and Central America, Europe and Asia during what has been an especially challenging year,” said Jeff Puritt, president and CEO of TELUS International. “Our company is built upon a caring culture that one can genuinely experience at all levels of our organisation; a culture which authentically and meaningfully prioritizes our team members’ well-being and growth, and supports their desire to be part of something bigger than themselves by providing opportunities to volunteer and make a positive impact in our communities. We fervently believe that this philosophy is key to our success, and view this recognition as validation of our passionate efforts and commitment over the course of many years.”

Driven by CEO Darren Entwistle’s visionary and compassionate leadership, the TELUS team continues to leverage its global leading networks and technology to help team members worldwide work, learn, socialize, and stay healthy at home, enabling business customers to support their clients, as well as expanding access to TELUS’ virtual healthcare solutions, relieving pressure on crowded hospitals, helping preserve capacity for those with urgent healthcare needs, and keeping patients safely at home.

About Forbes World’s Best Employers 2020
Forbes partnered with market research firm Statista to compile our fourth-annual list of the World’s Best Employers. We surveyed 160,000 full-time and part-time workers from 58 countries working for businesses with operations in multiple nations or regions. Surveys were conducted on a rolling basis from June to July, and participants were asked to rate their willingness to recommend their own employers to friends and family. They were also asked to rate their satisfaction with their employers’ Covid-19 responses and score their employers on image, economic footprint, talent development, gender equality and social responsibility. The final list is composed of 750 multinational and large corporations headquartered in 45 countries. To learn more about Forbes World’s Best Employers 2020 click here.

About TELUS
TELUS (TSX: T, NYSE: TU) is a dynamic, world-leading communications and information technology company with $15 billion in annual revenue and 15.4 million customer connections spanning wireless, data, IP, voice, television, entertainment, video and security. We leverage our global-leading technology to enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. TELUS Health is Canada’s largest healthcare IT provider, and TELUS International delivers the most innovative business process solutions to some of the world’s most established brands.

Driven by our passionate social purpose to connect all Canadians for good, our deeply meaningful and enduring philosophy to give where we live has inspired our team members and retirees to contribute $736 million and 1.4 million days of service since 2000. This unprecedented generosity and unparalleled volunteerism have made TELUS the most giving company in the world.

For more information about TELUS, please visit telus.com, follow us @TELUSNews on Twitter and @Darren_Entwistle on Instagram.

About TELUS International
TELUS International focuses on the value of human connection to design, build and deliver high-tech, high-touch customer experiences powered by next-gen digital solutions. With almost 50,000 team members and delivery centers across North and Central America, Europe and Asia, TELUS International empowers customer experience innovation through digital enablement, spirited teamwork, agile thinking, and a caring culture that puts customers first. The company’s solutions cover customer experience, content moderation, digital transformation, work-from-home, IT lifecycle, advisory and digital consulting, trust & safety, and back-office support. Fueling any stage of company growth, TELUS International partners with some of the world’s most disruptive brands from tech and games, communications and media, eCommerce and fintech, healthcare, and travel and hospitality. The company serves clients in over 50 languages. Learn more at: telusinternational.com

For more information, please contact:
Donna Ramirez
TELUS Media Relations
donna.ramirez@telus.com

SimonMed Imaging partners with Philips to deploy new diagnostic imaging technology to advance radiology workflow performance

October 21, 2020

SimonMed will introduce Philips’ state-of-the-art 3T MR services to help improve patient care while increasing patient and staff satisfaction at a lower cost

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that SimonMed Imaging, one of the largest outpatient imaging providers in the U.S., will bring the most advanced 3T MRI Philips technology to its centers of excellence across the U.S. The first MR systems, placed in California, Arizona, Illinois and Colorado, will feature software and services to enhance diagnoses ranging from brain injuries, liver and cardiac disease, to orthopedic injuries. Philips and SimonMed are also collaborating to further enhance the patient experience and speed in diagnostic imaging.

Advanced MR technology enhances patient experience and workflow efficiency
Faced with increased financial pressures and demands due in large part to COVID-19, imaging providers are dealing with a growing and aging co-morbid patient population who need and deserve the most advanced care. Driving day-to-day operations, while planning for long-term strategies, are necessary to continue to deliver consistent, high-quality care. Together with their customers, Philips takes a systems view approach to imaging that delivers an end-to-end solution, helping provide consistently high-quality imaging services to referring physicians so they can deliver more definitive diagnoses, clear care pathways and more predictable outcomes for patients.

Patients are at the heart of the Philips MR System Ingenia Elition 3.0T, providing an experience to SimonMed Imaging that enhances comfort while reducing the likelihood of rescans [1]. With up to 80% acoustic noise reduction, voice guidance, and comfortable table positioning, patients are made to feel at ease, resulting in smoother, faster exams [2]. With revolutionary sensing technology, Ingenia Elition delivers innovative patient comfort and enhanced workflow capabilities for faster and more patient-friendly exams. This new paradigm in productivity applies to all anatomies and anatomical contrasts.

“This collaboration with Philips focuses on going beyond routine 3T MRI imaging to deploy the most advanced technology, often only available to an academic center, in accessible and affordable outpatient practice to greatly enhance diagnoses from early post-traumatic brain injuries to the most subtle orthopedic injuries,” said Dr. John Simon, CEO, SimonMed Imaging. “Patients will literally have access to the entire spectrum of the newest techniques and enhanced diagnoses. Together with Philips, we continue our efforts to see beyond current technology as the rate of change is tremendous, and bring these powerful advancements to help benefit both providers and patients.”

“Now more than ever, we continue our commitment to advanced technology and efficient workflows to drive enhanced integration, virtualization and digitalization to deliver precision diagnoses required during these most challenging times. Providing our customers with a clear path to precision diagnosis and treatment to help achieve better outcomes at a lower cost of care is at the center of all we do,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “Our advanced MR technology, combined with our advanced integrated radiology workflows, is the latest innovation to further demonstrate our commitment in driving technology to help our forward-thinking customers like SimonMed advance care for their patients.”

Philips advanced MR systems at SimonMed Imaging
Philips MR systems, including the Ingenia Elition, offer cutting-edge MR imaging techniques, while setting new directions for clinical research in 3.0T imaging based on gradient and RF designs. The system delivers superb image quality and performs MRI exams up to 50% faster [3]. Having access to new diagnostic techniques, such as mapping the white matter to evaluate brain trauma, supports confident diagnosis even in the most challenging clinical indications.

Philips Live at RSNA 2020
Philips brings together smart diagnostic systems and optimized workflows with integrated diagnostic insights – including imaging, monitoring, laboratory, genomics and longitudinal data – to enable a clear care pathway with predictable outcomes for patients. At the RSNA 2020 virtual event, Philips will showcase an end-to-end systems view of imaging to provide consistently high-quality imaging services to deliver more definitive diagnoses. Visit Philips Live at RSNA 2020 for more information on Philips integrated workflow solutions to connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.

[1] Compared to the average number of rescans reported on the other five on-site Philips MR scanners without Ambient Experience and In-bore Connect. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[2] Compared to scanning without ComforTone.
[3] Compared to Philips scans without Compressed SENSE.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Alphawave IP Receives Prestigious 2020 TSMC OIP Partner of the Year Award for High-Speed SerDes IP

TORONTO, Oct. 21, 2020 (GLOBE NEWSWIRE) — Alphawave is pleased to announce that it has been recognized by TSMC as a recipient of 2020 OIP Partner of the Year Award for High-Speed SerDes IP. The OIP Partner of the Year awards honor TSMC Open Innovation Platform® (OIP) ecosystem partners like Alphawave demonstrating excellence in next-generation system-on-chip (SoC) and 3DIC design enablement over the past year.

Alphawave joined the TSMC IP Alliance program in March 2019, as a part of the TSMC Open Innovation Platform® (OIP), which accelerates innovation in the semiconductor design community. The 2020 TSMC OIP Partner of the Year award was given to Alphawave based on Alphawave’s multi-standard Serializer-Deserializer (MSS) technologies made available to customers on the TSMC 7nm and 5nm process technologies.

“The TSMC OIP Partner of the Year award for High-Speed SerDes IP is a prestigious honor for me personally, and the entire Alphawave team. In just three short years since we were founded, we have built a compelling portfolio of high speed interface IPs for TSMC processes and their customers. The OIP Partner of the Year award validates the tremendous customer successes we have experienced in both TSMC 7nm and 5nm processes,” said Tony Pialis, President and CEO of Alphawave. “As we innovate and expand our portfolio with TSMC in 5nm and beyond, we look forward to continue enabling our mutual customers globally. We are proud to be part of the effort in helping customers achieve silicon success.”

“I’m pleased to congratulate Alphawave as the winner of the 2020 TSMC OIP Partner of the Year award for High-Speed SerDes IP,” said Suk Lee, Senior Director of Design Infrastructure Management Division at TSMC. “We look forward to our continued partnership to address customers’ design challenges and extend the development of PPA-optimized design platforms for HPC, automotive, and AI/ML applications.”

The title of OIP Partner of the Year is awarded to partner companies achieving the highest standards of design, development, and technology implementation to accelerate silicon innovation. Alphawave will continue working with TSMC to enable next-generation SoC and 3DIC designs with certified solutions and services using TSMC’s latest technologies.

Additional information is available at the TSMC Press Center https://www.tsmc.com/tsmcdotcom/PRListingNewsAction.do?action=detail&language=E&newsid=PGGOISPGTH.

About Alphawave IP Inc.
Alphawave is a leading provider of multi-standard connectivity IP solutions for electronic devices. Founded in Toronto, Ontario, Canada in 2017, Alphawave is one of the fastest growing and most profitable companies in the semiconductor industry. Find out more at http://www.awaveip.com.

Alex Mann
alex.mann@awaveip.com

CNH Industrial to announce 2020 Third Quarter financial results on November 5, 2020

London, October 21, 2020

CNH Industrial (NYSE: CNHI / MI: CNHI) announced today that its financial results for the Third Quarter of 2020 will be released on Thursday, November 5, 2020.

A live audio webcast of the 2020 Third Quarter results conference call will begin at 3:30 p.m. CET/ 2:30 p.m. GMT / 9:30 a.m. EST on Thursday, November 5, 2020.

Details for accessing the webcast presentation are available at the following address: http://bit.ly/CNH_Industrial_Q3_2020.

For those unable to participate in the live session, a replay will remain archived in the Investors section of the corporate website (www.cnhindustrial.com) for two weeks following the conference call.

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Contacts:

Corporate Communications

Email: mediarelations@cnhind.com

Investor Relations

Email: investor.relations@cnhind.com

Attachment

Philips and Marienhospital Stuttgart sign 10-year strategic partnership to improve patient care and efficiency

October 21, 2020

  • Long-term agreement guarantees access to state-of-the-art solutions, controls costs, and ensures security of future investment
  • Fully-integrated approach deploying Philips’ digital healthcare solutions across multiple departments to enhance the experience of Marienhospital Stuttgart’s patient and staff

Amsterdam, the Netherlands and Stuttgart, Germany – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Marienhospital Stuttgart (Germany) today signed a 10-year strategic partnership agreement to expand world-class medicine at the hospital and provide integrated patient care. The project will include renewal and ongoing development of the hospital’s diagnostic imaging equipment and associated IT systems, digitization of its pathology department, and enhancement of the hospital’s emergency medicine capabilities.

Rather than treating each of these improvement areas as a separate exercise, Philips and Marienhospital Stuttgart will integrate them into connected patient care and optimized efficiency solutions. This will involve analysis of the hospital’s current treatment structures and pathways to enhance the overall quality of the hospital’s structures, processes and results, while also identifying potential cost savings. By jointly developing needs-based technology solutions, Marienhospital Stuttgart will be able to better plan its costs and ensure investment security in all areas.

“Due to the long-term nature of our partnership with Philips, our hospital will not only actively participate in future technological advances in healthcare, but also become a leader,” said Markus Mord, Managing Director of Marienhospital Stuttgart. “It will enable us to offer our patients diagnostic and therapeutic procedures that consistently meet the latest standards. We live medicine and always focus on the well-being of our patients.”

“As a solution provider, we specialize in partnering with our customers to provide integrated care concepts that enhance treatment pathways for their patients,” said Peter Vullinghs, Managing Director Philips DACH. “With new, highly innovative approaches, we will help to enhance the quality of medical care for the benefit of the patient across the board. We look forward to many years of mutual cooperation with Marienhospital Stuttgart.”

Reliable diagnosis through digital pathology
A core element of the collaboration is redesign of the hospital’s pathology department workflow, replacing conventional microscopes and glass slides with Philips’ high-performance digital pathology slide scanners and computer workstations. This will allow slide images to be managed, displayed, analyzed and discussed with clinical colleagues – for example, during tumor boards for the diagnosis and treatment of cancers. The ability to share slide images will also enable virtual consultations with experts from other hospitals. Competence networks like this combine the experience of doctors working in the clinic with the knowledge of their research colleagues, speeding up right-first-time diagnosis and the initiation of therapy.

Radiology for current and future needs
Reflecting the holistic nature of the partnership model, Philips will also help to analyze and redefine Marienhospital Stuttgart’s radiology procedures, processes and IT systems, as well as coordinating equipment renewal and expansion. Under the terms of the agreement, Philips will be responsible for the procurement, installation, maintenance (including updates and upgrades) and servicing of all large radiology equipment, with an obligation to ensure the availability of equipment in line with the strategic orientation of the hospital.

Emergency medicine for enhanced patient and staff experiences
As the first point of contact for patients with acute health problems, Marienhospital Stuttgart’s Clinic for Emergency Medicine plays a central role in its care concept. A working group from Philips and the hospital has already examined the clinic’s current status and development potential against the background of a holistic care approach, including assessment of patient safety, processes, procedures, technical equipment and staff working conditions. The knowledge gained from this will be incorporated into the clinic’s future structural planning and implementation.

For further information, please contact:

Mark Groves
Philips Group Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

Annette Halstrick
PR Manager Philips DACH
Tel: +49 152 2280 0529
Email: annette.halstrick@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Marienhospital Stuttgart
The Marienhospital Stuttgart was founded in 1890. It is still owned by the Sisters of Mercy of Saint Vincent de Paul in Untermarchtal. From a small hospital with 15 nuns and 90 beds, it has developed into a large hospital and today has 761 beds and well over 2,000 employees. Marienhospital Stuttgart regularly receives recognition from independent institutions such as health insurance companies, magazines and associations; among other things as one of the best hospitals and one of the best employers in Germany.

From the beginning, two characteristics have been one of the cornerstones of the hospital: human attention to the patient and medicine that was technically always up-to-date or ahead of its time. As early as 1908, the hospital was one of the first hospitals to acquire an X-ray machine and in the 130 years of its existence it has always been one of the most technically advanced hospitals in Germany. More about Marienhospital Stuttgart: https://www.marienhospital-stuttgart.de

Attachment

Sinch AB (publ): Sinch receives regulatory approval for the acquisition of SAP Digital Interconnect

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH

Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announces that it has been granted regulatory approval for the acquisition of SAP Digital Interconnect, a unit within SAP, from the Competition and Markets Authority in the United Kingdom. This means that regulatory approval has now been granted in all relevant jurisdictions and that closing of the transaction can proceed as planned during H2 2020.

Sinch announced the acquisition of SAP Digital Interconnect on 5 May, 2020. The acquisition is financed using cash at hand and available credit facilities.

Sinch has a financial target to maintain net debt/adjusted EBITDA below 2.5x over time. At the end of Q2 2020, Sinch had a net cash position with net debt/adjusted EBITDA of -2.1x. On a pro forma basis, which includes Adjusted EBITDA in acquired entities over the past 12 months, Net debt/Adjusted EBITDA would have been 2.2x if the acquisitions of ACL Mobile, SAP Digital Interconnect and Wavy had been closed by Q2 2020.

For further information, please contact

Thomas Heath
Chief Strategy Officer and Head of Investor Relations
Sinch AB (publ)
Mobile: +46-722-45 50 55
E-mail: thomas.heath@sinch.com

About Sinch

Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile messaging, voice and video. Sinch is a trusted software provider to mobile operators, and its platform powers business-critical communications for many of the world’s largest companies. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has local presence in more than 30 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com.

This information is information that Sinch AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 09:00 CET on October 21, 2020.

Attachment

Jeito Capital becomes major investor in SparingVision as part of €44.5 Million financing

Rafaèle Tordjman Launches JEITO CAPITAL, a New Private Equity Company  Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of JEITO  I at €200 Million

Jeito Capital becomes major investor in SparingVision as part of €44.5 Million financing

  • Jeito Capital has selected SparingVision as its first French investment following the fund I launch in January 2020
  • SparingVision is focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases

Paris, France, 21 October 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has become a major investor in SparingVision, a French preclinical stage biotech company focused on gene therapy in ophthalmology. The €44.5 million financing round brought together new investors alongside Jeito including 4BIO Capital, University of Pittsburgh Medical Center Enterprise and Ysios Capital; along with further investment from current holders, Bpifrance and Foundation Fighting Blindness. SparingVision becomes Jeito’s first French, and second European, after Neogene Therapeutics, investment following Jeito’s fund I launch in January 2020.

Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment, SPVN06, for the mutation-agnostic treatment of retinitis pigmentosa (“RP”). Most notably, the funding will support SparingVision’s GMP activities (including the manufacturing of a first clinical batch of the product, currently ongoing), the IND/CTA regulatory activities and the conduct of a first-in-man study, scheduled to start in 2021. The company also intends to further expand its management team and commence operations in the US.

SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy consisting of one neurotrophic factor and one oxidative stress reducing enzyme which, acting synergistically, aim to slow or stop the degeneration of photoreceptors. Loss of photoreceptors leads to blindness in RP, one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved for RP patients independently of their genetic background.

SparingVision also announces today that the company’s Chairman of the Board, Stéphane Boissel, has been appointed Chief Executive Officer of the company. Sabine Dandiguian, Managing Partner at Jeito, will join the SparingVision Board.

Rafaèle Tordjman, Founder and CEO at Jeito, said:We are delighted to become a significant investor in financing SparingVision’s new round, which marks our first French investment since Jeito’s launch and brings together a strong syndicate of investors from the US and across Europe, including France, the UK and Spain. SparingVision has made significant progress since its creation in 2016 and has the potential to provide a breakthrough treatment for patients suffering from retinitis pigmentosa, the most common inherited retinal degeneration for which there is currently no approved therapy to treat all genetic forms. The company has an ambitious strategy and we look forward to providing the leadership team with long term, strategic support as the company expands its business, progresses its lead therapy into clinical development and builds out its portfolio in ophthalmology.

“Jeito’s deal flow continues to be strong in Europe and beyond, and we remain on track to announce future investments in due course.”

Stéphane Boissel, SparingVision’s President and Chief Executive Officer, said: “We are delighted to have closed this financing round, which demonstrates the excitement around SparingVision’s lead compound, SPVN06. With its singular mutation-agnostic approach, SPVN06 could have a much broader commercial potential than most gene therapy products for RP currently in development and will be used as an anchor to build an economically-viable portfolio of therapies in the field of ophthalmology. Our shareholders, both new and existing, are all long term, strategic and patient-centric investors that share our vision and we are excited to be working with them to achieve our goals.”

About Jeito Capital
Jeito Capital is an international investment company with a patient benefit driven approach that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. Jeito has a unique, long-term investment strategy, with the aim of providing continuity from clinical development to market access for breakthrough drugs with validated proofs of concept. This continuity is expressed both in the support provided to entrepreneurs by the Jeito Capital team and by the investment of significant capital to ensure the growth of companies, the acceleration towards commercialization and faster access to these major innovations.  Jeito Capital is based in Paris with a presence in Europe and the United States.

About SparingVision
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million worldwide. SparingVision is a spin-off of the Paris Vision Institute. SparingVision’s investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com

For more information please contact:

Jeito Capital

Rafaèle Tordjman, Founder and CEO

contact@jeito.life

Consilium Strategic Communications

Mary-Jane Elliott / Melissa Gardiner / Kris Lam

Jeito@consilium-comms.com

Steele & Holt (France)

Servane Taslé : servane@steeleandholt.com

Anaïs Miegeville : anais@steeleandholt.com

Tel: + 33 (0) 6 35 36 35 00

Tel: +44 (0) 20 3709 5700

Tel: +33 6 66 58 84 28

Tel: +33 6 33 73 85 16